Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment
出版年份 2021 全文链接
标题
Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment
作者
关键词
-
出版物
Cancers
Volume 13, Issue 20, Pages 5080
出版商
MDPI AG
发表日期
2021-10-12
DOI
10.3390/cancers13205080
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
- (2021) Kun-Huei Yeh et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies
- (2021) Roberto Moretto et al. BRITISH JOURNAL OF CANCER
- Neutrophil Extracellular Traps in Colorectal Cancer Progression and Metastasis
- (2021) Umama Khan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread
- (2021) Hung-Chih Hsu et al. Scientific Reports
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
- (2020) John A Bridgewater et al. LANCET ONCOLOGY
- Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
- (2020) Alena Novakova-Jiresova et al. Cancer Management and Research
- How we treat metastatic colorectal cancer
- (2020) Vincenzo De Falco et al. ESMO Open
- The Role of Tumor-Associated Neutrophils in Colorectal Cancer
- (2019) Rei Mizuno et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inflammation and Cancer: Triggers, Mechanisms, and Consequences
- (2019) Florian R. Greten et al. IMMUNITY
- Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
- (2019) Tanios S Bekaii-Saab et al. LANCET ONCOLOGY
- Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study
- (2019) Michel Ducreux et al. EUROPEAN JOURNAL OF CANCER
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer
- (2018) Lars Mortimer Schiffmann et al. BRITISH JOURNAL OF CANCER
- Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial
- (2017) Takayuki Yoshino et al. EUROPEAN JOURNAL OF CANCER
- Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer
- (2017) Elizabeth M. Cespedes Feliciano et al. JAMA Oncology
- Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
- (2016) F Pietrantonio et al. ANNALS OF ONCOLOGY
- Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program
- (2016) Antoine Adenis et al. BMC CANCER
- Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer
- (2016) Maria Rosaria Galdiero et al. INTERNATIONAL JOURNAL OF CANCER
- Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC).
- (2016) Michael Teufel et al. JOURNAL OF CLINICAL ONCOLOGY
- Neutrophil count is the most important prognostic component of the differential white cell count in patients undergoing elective surgery for colorectal cancer
- (2015) David G. Watt et al. AMERICAN JOURNAL OF SURGERY
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer
- (2015) Imran Bhatti et al. International Journal of Surgery
- Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.
- (2015) Michela Del Prete et al. Oncotarget
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
- (2014) Gerald W. Prager et al. CANCER SCIENCE
- Soluble Carcinoembryonic Antigen Activates Endothelial Cells and Tumor Angiogenesis
- (2013) K. H. Bramswig et al. CANCER RESEARCH
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004
- (2008) H. J. Meulenbeld et al. ANNALS OF ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search